Aiwu Ruth He, MD, PhD
Precision medicine is rapidly evolving in the gastrointestinal (GI) malignancies space, with biomarker testing opening up options for the treatment of these diseases. This puts a greater importance on molecular testing for patients, says Aiwu Ruth He, MD, PhD.
State of the Science Summit™ on Gastrointestinal Cancers, He, an associate professor of medicine at the Georgetown-Lombardi Comprehensive Cancer Center, discussed the future of precision medicine in GI cancers.
OncLive: Please provide an overview of the panel that you moderated at the State of the Science Summit.
: We had 4 excellent faculty who talked about the updates to pancreatic and hepatobiliary cancer treatment, treatment of neuroendocrine tumors (NETs) of the GI tract, and precision medicine. Molecular profiling has been identified as a very important tool in pancreatic and biliary cancer. Some of the faculty spoke about liquid biopsies and the importance of taking a biopsy of a patient’s tumor early, as there is increasing evidence showing that specific targeted genetic alterations can lead to treatment that may change a patient's outcomes.
... to read the full story